BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery
2020年9月29日 - 9:00PM
BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of
comprehensive solutions for cardiovascular regenerative
therapies, today announced the issuance of U.S. Patent No:
10,780,248 for a “Radial and Transendocardial Delivery Catheter”
that further protects the Helix™ Biotherapeutic Delivery System and
enhances its cell therapy delivery capabilities. The patent does
not expire until after September 29, 2034.
This patent covers a needle injection catheter system
appropriate for transradial biotherapeutic delivery to the heart,
and strengthens the Company’s clinical stage biotherapeutic
programs in heart failure and chronic myocardial ischemia.
“Delivery is critically important to successful biotherapeutic
treatment. You can have a promising cell therapy, but if sub-par
delivery doesn’t facilitate biologic retention by the heart or has
a poor safety profile, it can cause a therapy to fail,” said
BioCardia CEO Peter Altman, PhD. “At BioCardia, we have always
recognized the important role delivery plays in the overall success
of our therapeutics and in their promise to improve the lives of
millions of patients with heart disease. This additional patent
protection for our Helix system used in a transradial approach
accessing the heart through an artery in the wrist, in addition to
the transfemoral approach, enables us to offer the most robust
delivery capabilities of any cell therapy developer.”
Cardiac catheter insertion through the small transradial artery
in the wrist is growing in popularity as a delivery approach for
percutaneous coronary interventions (PCI). It is used outside of
the U.S. in more than 23 percent of PCIs, according to some
estimates.1 This level of adoption is due to increasing evidence
that transradial delivery increases patient safety by reducing
bleeding complications, and may help reduce costs by decreasing
hospital admissions, length of stay and patient risk.2 Transradial
artery PCI is expected to reduce costs to the healthcare system
through same-day discharge, which costs nearly $3,700 less than
transfemoral PCI without same-day discharge.3
About BioCardia®BioCardia, Inc., headquartered
in San Carlos, California, is developing autologous and allogenic
cell-based therapies to treat cardiovascular disease. CardiAMP™ and
CardiALLO™ cell therapies are the Company’s biotherapeutic product
candidates in clinical development. The Company has also developed
a portfolio of approved enabling products that optimize delivery of
its cell therapies.
Forward Looking Statements This press release
contains forward-looking statements that are subject to many risks
and uncertainties. Forward-looking statements include, among other
things, references to the robustness the Company’s delivery system
capabilities and the level of adoption and anticipated cost
reductions associated with transradial procedures for PCI.
We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” “approximately” or other words that convey the
uncertainty of future events or outcomes to identify these
forward-looking statements. Although we believe that we have a
reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results may
differ materially from the forward-looking statements contained in
this press release. As a result of these factors, we cannot assure
you that the forward-looking statements in this press release will
prove to be accurate. Additional factors that could
materially affect actual results can be found in our documents
filed with the SEC, including our recent filings on Form 8-K, Form
10-K and Form 10-Q, particularly any statements under the caption
entitled “Risk Factors” therein.” BioCardia expressly disclaims any
intent or obligation to update these forward-looking statements,
except as required by law.
References
- Valle JA, Kaltenbach LA, Bradley SM, et al. Variation in the
adoption of transradial access for ST-segment elevation myocardial
infarction: insights from the NCDR CathPCI Registry. JACC
Cardiovasc Interv. 2017;10:2242-2254.
- Ferrante G, Rao SV, Jüni P, et al. Radial versus femoral access
for coronary interventions across the entire spectrum of patients
with coronary artery disease: a meta-analysis of randomized trials.
JACC Cardiovasc Interv. 2016;9:1419-1434.
- Amin AP, Patterson M, House JA, et al. Costs associated with
access site and same-day discharge among Medicare beneficiaries
undergoing percutaneous coronary intervention: an evaluation of the
current percutaneous coronary intervention care pathways in the
United States. JACC Cardiovasc Interv. 2017;10:342-351.
Media Contact: Michelle McAdam, Chronic
Communications, Inc.michelle@chronic-comm.com (310)
902-1274
Investor Contact: David McClung, Chief
Financial OfficerInvestors@BioCardia.com (650)
226-0120
BioCardia (NASDAQ:BCDAW)
過去 株価チャート
から 10 2024 まで 11 2024
BioCardia (NASDAQ:BCDAW)
過去 株価チャート
から 11 2023 まで 11 2024